Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Sells $176,661.21 in Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,057 shares of the stock in a transaction on Monday, February 11th. The shares were sold at an average price of $13.53, for a total transaction of $176,661.21. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Wednesday, February 6th, Matt Davidson sold 15,859 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $12.93, for a total transaction of $205,056.87.
  • On Friday, February 1st, Matt Davidson sold 10,298 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.95, for a total transaction of $123,061.10.
  • On Tuesday, January 29th, Matt Davidson sold 10,220 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.94, for a total transaction of $111,806.80.
  • On Thursday, January 24th, Matt Davidson sold 3,100 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.12, for a total transaction of $31,372.00.
  • On Friday, January 18th, Matt Davidson sold 5,765 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.26, for a total transaction of $59,148.90.
  • On Tuesday, January 15th, Matt Davidson sold 8,019 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.53, for a total transaction of $84,440.07.
  • On Thursday, January 10th, Matt Davidson sold 15,802 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.87, for a total transaction of $171,767.74.
  • On Monday, January 7th, Matt Davidson sold 33,276 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.80, for a total transaction of $326,104.80.
  • On Wednesday, January 2nd, Matt Davidson sold 1,000 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.25, for a total transaction of $8,250.00.
  • On Thursday, December 27th, Matt Davidson sold 4,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total transaction of $32,882.00.

Shares of VRCA stock traded down $1.08 during trading hours on Monday, reaching $12.99. The stock had a trading volume of 55,222 shares, compared to its average volume of 53,497. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.03). As a group, research analysts forecast that Verrica Pharmaceuticals Inc will post -1.17 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $28,000. Beck Mack & Oliver LLC bought a new position in Verrica Pharmaceuticals in the 4th quarter valued at about $82,000. Bank of New York Mellon Corp bought a new position in Verrica Pharmaceuticals in the 3rd quarter valued at about $195,000. Capital Investment Advisory Services LLC grew its position in Verrica Pharmaceuticals by 15.9% in the 4th quarter. Capital Investment Advisory Services LLC now owns 12,400 shares of the company’s stock valued at $101,000 after buying an additional 1,700 shares in the last quarter. Finally, Asymmetry Capital Management L.P. grew its position in Verrica Pharmaceuticals by 28.1% in the 3rd quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock valued at $1,249,000 after buying an additional 16,885 shares in the last quarter. 32.55% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 5th.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2019/02/11/verrica-pharmaceuticals-inc-vrca-major-shareholder-sells-176661-21-in-stock.html.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Featured Story: Momentum Investing

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply